Outcome of Board Meeting for Considered and Approved the Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab's board, meeting on February 13, 2026, approved the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025. On a consolidated basis, revenue from operations grew about 29% YoY to Rs 17,891.89 lakhs for the nine-month period (vs Rs 13,869.93 lakhs), while quarterly revenue jumped to Rs 6,294.15 lakhs from Rs 4,021.61 lakhs a year ago, driven largely by subsidiary Naxpar Pharma Private Limited. Consolidated profit after tax for 9M rose to Rs 961.67 lakhs (vs Rs 861.35 lakhs), with Q3 PAT more than doubling to Rs 271.86 lakhs. Standalone numbers are small but show sharp sequential recovery, with Q3 PAT at Rs 70.91 lakhs vs Rs 15.78 lakhs in the year-ago quarter. The results include an exceptional charge of Rs 2.16 lakhs standalone and Rs 113.80 lakhs consolidated, arising from the November 2025 Labour Codes notification impacting gratuity calculations. Auditor C. N. Patel & Co. issued a clean limited review report with no qualifications.
Strong consolidated revenue and profit growth, primarily driven by the Naxpar Pharma subsidiary, should be viewed positively by investors, though the one-time Labour Code-related exceptional charge slightly weighed on pre-tax profits. Standalone operations remain modest in size but are showing a clear turnaround in Q3, supporting the overall growth narrative.